A flow cytometry‐based assay to measure neutralizing antibodies against <scp>SARS‐CoV</scp>‐2 virus-Reference-Cited by-同舟云学术

A flow cytometry‐based assay to measure neutralizing antibodies against SARS‐CoV‐2 virus

Published:2024-04-16 Issue:6 Volume:105 Page:446-457
ISSN:1552-4922
Container-title:Cytometry Part A
language:en
Short-container-title:Cytometry Pt A

Author:

Pscheidt Veridiane M.¹^ORCID,de Souza Priscila Oliveira¹,Fazolo Tiago¹,Modena José Luiz Proença²,Simeoni Camila²,Teixeira Daniel²,Silva Natália Brunetti²,dos Santos Karina Bispo²,Júnior Luiz Rodrigues¹,Bonorino Cristina¹³

Affiliation:

1. Immunotherapy Laboratory – (LAIT) – Department of Basic Health Sciences of Federal University of Health Sciences of Porto Alegre UFCSPA Porto Alegre Brazil

2. Laboratory of Emerging Viruses (LEVE) – Department of Genetics, Evolution, Microbiology and Immunology University of Campinas – UNICAMP – Campinas São Paulo Brazil

3. Department of Surgery University of California at San Diego – UCSD La Jolla California USA

Abstract

AbstractThe COVID‐19 pandemic caused by the SARS‐CoV‐2 virus has highlighted the need for serological assays that can accurately evaluate the neutralizing efficiency of antibodies produced during infection or induced by vaccines. However, conventional assays often require the manipulation of live viruses on a level‐three biosafety (BSL3) facility, which presents practical and safety challenges. Here, we present a novel, alternative assay that measures neutralizing antibodies (NAbs) against SARS‐CoV‐2 in plasma using flow cytometry. This assay is based on antibody binding to the S protein and has demonstrated precision in both intra‐ and inter‐assay measurements at a dilution of 1:50. The cut‐off was determined using Receiver Operating Characteristic (ROC) analysis and the value of 36.01% has shown high sensitivity and specificity in distinguishing between pre‐pandemic sera, COVID‐19 patients, and vaccinated individuals. The efficiency significantly correlates with the gold standard test, PRNT. Our new assay offers a safe and efficient alternative to conventional assays for evaluating NAbs against SARS‐CoV‐2.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.a.24838

Reference25 articles.

1. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

2. A pneumonia outbreak associated with a new coronavirus of probable bat origin

3. WHO.WHO Director‐General's opening remarks at the media briefing on COVID‐19 – 11 March 2020.2020.

4. The M Protein of SARS-CoV: Basic Structural and Immunological Properties

5. Neutralizing antibody responses to SARS‐CoV‐2 in a COVID‐19 recovered patient cohort and their implications;Wu F;SSRN Electron J,2020